Ginsenoside Rb1 alleviates bleomycin-induced pulmonary inflammation and fibrosis.

PMID: Drug Des Devel Ther. 2022; 16: 1793-1809. Epub 2022 Jun 13. PMID: 35719213 Abstract Title: Ginsenoside Rb1 Alleviates Bleomycin-Induced Pulmonary Inflammation and Fibrosis by Suppressing Central Nucleotide-Binding Oligomerization-, Leucine-Rich Repeat-, and Pyrin Domains-Containing Protein Three Inflamome Act Pathway. Abstract: Purpose: Idiopathic pulmonary fibrosis is a chronic and irreversible fibrotic interstitial pneumonia of unknown etiology … Read more

Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension.

PMID: Phytomedicine. 2022 May 23; 102: 154171. Epub 2022 May 23. PMID: 35636165 Abstract Title: Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response. Abstract: BACKGROUND: Pulmonary hypertension (PH) is a progressive disorder lacking a validated and effective therapy … Read more

Exploring the mechanism whereby sinensetin delays the progression of pulmonary fibrosis.

PMID: Front Pharmacol. 2021; 12: 693061. Epub 2021 Jun 18. PMID: 34220517 Abstract Title: Exploring the Mechanism Whereby Sinensetin Delays the Progression of Pulmonary Fibrosis Based on Network Pharmacology and Pulmonary Fibrosis Models. Abstract: The incidence of pulmonary fibrosis (PF), a progressively fatal disease, has increased in recent years. However, there are no effective medicines … Read more